Search Results
Dec 18, 2025, 01:08 ET 69-Year-Old Patient from Kazakhstan Reclaims Her Life with a Single Daily Pill Through Precision Oncology
grandmother and an avid walker from Kazakhstan, began experiencing persistent breathlessness. A former smoker, she was diagnosed with Stage IV non-small cell lung cancer (NSCLC). Despite undergoing two rounds of chemotherapy locally, her symptoms worsened, prompting the family to travel over 2,500 km to seek advanced
More news about: Apollo Athenaa
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
The Journal of Clinical Oncology in 2023.About Non-Small Cell Lung Cancer (NSCLC)Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.13,14 The main subtypes of NSCLC are adenocarcinoma, squamous
More news about: Johnson & Johnson
Dec 17, 2025, 16:11 ET Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand
More news about: Achieve Life Sciences
Dec 17, 2025, 16:01 ET Insmed Provides Clinical and Business Update
critical homeostatic and tissue healing pathways intact. Insmed plans to advance Phase 2 development programs for INS1148 initially in interstitial lung disease and moderate-to-severe asthma. INS1148 (formerly known as OpSCF) was developed by Opsidio, a private, clinical-stage company.Dr. Flammer
More news about: Insmed Incorporated
Dec 17, 2025, 10:31 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Dec 17, 2025, 08:49 ET Eon Launches 5.0 Platform to Address Healthcare's Growing 'Validation Burden'
future."We've found the time it takes to review lung cancer screening exam results and move patients into their care pathway has gone from approximately six minutes to about ninety seconds," said Cindy Lambdin, RN, MS, nurse manager, Lung Cancer Screening, Henry Ford Health. "This has helped us
More news about: Eon
Dec 17, 2025, 08:47 ET NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio
clinical programs have advanced LSAM investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. Feasibility of the PurcisionTM platform has been established in taxanes, platins,
More news about: NanOlogy, LLC
Dec 17, 2025, 08:45 ET Volition Issues Business Review 2025
first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced
More news about: VolitionRx Limited
Dec 17, 2025, 08:30 ET IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Dec 17, 2025, 07:00 ET Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
currently in developmentAstraZeneca is advancing rilvegostomig in a broad development program including 11 ongoing Phase 3 trials in patients with lung, gastrointestinal, and endometrial cancers"This strategic agreement with AstraZeneca reflects the potential significant value of rilvegostomig
More news about: Compugen Ltd.
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.Pneumonitis/Interstitial lung disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated with PADCEV.When PADCEV was given in combination
More news about: Astellas Pharma Inc.
Dec 17, 2025, 06:18 ET Karmanos Cancer Institute Welcomes New Medical Oncologist to Thoracic Oncology and Phase I Clinical Trials Teams
the thoracic oncology team, Dr. Choucair specializes in treating esophageal cancer, lung cancer, mesothelioma, thymoma, and thymic carcinoma. His research interests are in thoracic oncology biomarkers, small cell lung cancer (SCLC) therapies, precision oncology and tumor agnostic therapies, immune therapies
More news about: Karmanos Cancer Institute
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] BD Contacts:Ariel
More news about: Antengene Corporation Limited
Dec 16, 2025, 17:00 ET Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda. The Company also provided a brief progress update on the expansion cohorts investigating ozekibart in combination
More news about: Inhibrx Biosciences, Inc.
Dec 16, 2025, 13:17 ET Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Conference on Lung Cancer, demonstrating clinically meaningful outcomes for firmonertinib in EGFR PACC mutant non-small cell lung cancer, advancing
More news about: USA News Group
Dec 16, 2025, 08:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
early clinical data for ALK202 have provided preliminary support of the EGFR/cMET bispecific ADC's potential as a cornerstone therapy in non-small cell lung cancer. Furthermore, the program is being expanded into clinical evaluation of a broader range of biomarker-defined tumor types and patient populations.AllinkBio
More news about: Allink Biotherapeutics
Dec 16, 2025, 05:02 ET Kick the Nic in 2026: American Lung Association Offers Support to Help People Quit All Nicotine and Tobacco Products for Good
www.lung.org/openenrollment.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Dec 16, 2025, 02:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
early clinical data for ALK202 have provided preliminary support of the EGFR/cMET bispecific ADC's potential as a cornerstone therapy in non-small cell lung cancer. Furthermore, the program is being expanded into clinical evaluation of a broader range of biomarker-defined tumor types and patient populations.AllinkBio
More news about: Allink Biotherapeutics
Dec 15, 2025, 16:00 ET AZmed Expands Into CT Imaging With CE-Marked AZnod, An AI Tool for Lung Nodule Detection and the First Product in the Rayscan® Line
AZnod is designed to aid lung cancer screening programs by providing standardized detection and comprehensive characterization of pulmonary nodules on CT scans.Lung cancer screening procedures place an interpretive load on medical imaging teams
More news about: AZmed
Dec 15, 2025, 11:46 ET Brayton Purcell LLP Highlights Massachusetts Safety Alert After State's First Silicosis Case in Artificial Stone Industry
Silicosis is a progressive, incurable lung disease caused by inhaling silica particles. Crystalline silica artificial stone—also referred to as "quartz" or "engineered stone"—contains at least
More news about: Brayton Purcell LLP
Dec 15, 2025, 11:23 ET Detect-ION Launches Collaborative Project to Develop Breath-Based Diagnostics for Pneumonia-Causing Pathogens
develop a non-invasive breath test for detecting Pseudomonas aeruginosa – one of the leading causes of pneumonia in lung transplant recipients and patients with structural lung diseases.
More news about: Detect-ION
Dec 15, 2025, 08:45 ET Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Dec 15, 2025, 07:00 ET EYLSIA NICOLAS TRIUMPHS WITH PATENT AWARD, CHART RECORDS, AND INSPIRING JOURNEY OF RESILIENCE
to a year defined by extraordinary resilience and artistic achievement. In 2025, Nicolas faced the daunting challenge of losing 20% of her lung capacity and sustaining damage to her vocal cords. Rather than retreat, she turned to her pioneering sound technology and artificial intelligence
More news about: Eylsia Nicola
Dec 12, 2025, 16:29 ET Oklahoma Proton Center lauds results of groundbreaking clinical study
state-of-the-art cancer treatment. The center treats over 750 patients a year across multiple disease sites including head and neck, brain, breast, prostate, lung, esophageal, lymphoma, sarcoma, and pediatric cancers. For more information about proton therapy or to see if you are a candidate please visit
More news about: Oklahoma Proton Center
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
estimates.4About Breast CancerBreast cancer is the second most commonly diagnosed cancer worldwide (following lung cancer), according to GLOBOCAN. The estimated 2.3 million new cases indicate that close to 1 in every 4 cancers diagnosed in 2022 is breast cancer.
More news about: Eli Lilly and Company